Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review
dc.contributor.author | Petrou, Myria | en_US |
dc.contributor.author | Dwamena, Ben A. | en_US |
dc.contributor.author | Foerster, Bradley R. | en_US |
dc.contributor.author | MacEachern, Mark P. | en_US |
dc.contributor.author | Bohnen, Nicolaas I. | en_US |
dc.contributor.author | Müller, Martijn Ltm | en_US |
dc.contributor.author | Albin, Roger L. | en_US |
dc.contributor.author | Frey, Kirk A. | en_US |
dc.date.accessioned | 2015-07-01T20:55:54Z | |
dc.date.available | 2016-07-05T17:27:58Z | en |
dc.date.issued | 2015-06 | en_US |
dc.identifier.citation | Petrou, Myria; Dwamena, Ben A.; Foerster, Bradley R.; MacEachern, Mark P.; Bohnen, Nicolaas I.; Müller, Martijn Ltm ; Albin, Roger L.; Frey, Kirk A. (2015). "Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review." Movement Disorders 30(7): 928-935. | en_US |
dc.identifier.issn | 0885-3185 | en_US |
dc.identifier.issn | 1531-8257 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/111915 | |
dc.description.abstract | BackgroundVarying degrees of cortical amyloid deposition are reported in the setting of Parkinsonism with cognitive impairment. We performed a systematic review to estimate the prevalence of Alzheimer disease (AD) range cortical amyloid deposition among patients with Parkinson's disease with dementia (PDD), Parkinson's disease with mild cognitive impairment (PD‐MCI) and dementia with Lewy bodies (DLB). We included amyloid positron emission tomography (PET) imaging studies using Pittsburgh Compound B (PiB).MethodsWe searched the databases Ovid MEDLINE, PubMed, Embase, Scopus, and Web of Science for articles pertaining to amyloid imaging in Parkinsonism and impaired cognition. We identified 11 articles using PiB imaging to quantify cortical amyloid. We used the metan module in Stata, version 11.0, to calculate point prevalence estimates of patients with “PiB‐positive” studies, that is, patients showing AD range cortical Aβ‐amyloid deposition. Heterogeneity was assessed. A scatterplot was used to assess publication bias.ResultsOverall pooled prevalence of “PiB‐positive” studies across all three entities along the spectrum of Parkinson's disease and impaired cognition (specifically PDD, PD‐MCI, and DLB) was 0.41 (95% confidence interval [CI], 0.24‐0.57). Prevalence of “PiB‐positive” studies was 0.68 (95% CI, 0.55‐0.82) in the DLB group, 0.34 (95% CI, 0.13‐0.56) in the PDD group, and 0.05 (95% CI, −0.07‐0.17) in the PD‐MCI group.ConclusionsSubstantial variability occurs in the prevalence of “PiB‐positive” studies in subjects with Parkinsonism and cognitive impairment. Higher prevalence of PiB‐positive studies was encountered among subjects with DLB as opposed to subjects with PDD. The PD‐MCI subjects showed overall lower prevalence of PiB‐positive studies than reported findings in non–PD‐related MCI. © 2015 International Parkinson and Movement Disorder Society | en_US |
dc.publisher | American Psychiatric Association | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | DLB | en_US |
dc.subject.other | MCI | en_US |
dc.subject.other | PDD | en_US |
dc.subject.other | Parkinson's disease | en_US |
dc.subject.other | systematic review | en_US |
dc.title | Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/111915/1/mds26191.pdf | |
dc.identifier.doi | 10.1002/mds.26191 | en_US |
dc.identifier.source | Movement Disorders | en_US |
dc.identifier.citedreference | Villemagne VL, Ong K, Mulligan RS, et al. Amyloid imaging with (18)F‐florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011; 52: 1210 ‐ 1217. | en_US |
dc.identifier.citedreference | Gomperts SN, Locascio JJ, Marquie M, et al. Brain amyloid and cognition in Lewy body diseases. Mov Disord 2012; 27: 965 ‐ 973. | en_US |
dc.identifier.citedreference | Gomperts SN, Locascio JJ, Rentz D, Santarlasci A, Marquie M, Johnson KA, Growdon JH. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013; 80: 85 ‐ 91. | en_US |
dc.identifier.citedreference | Rowe CC, Ng S, Ackermann U, et al. Imaging beta‐amyloid burden in aging and dementia. Neurology 2007; 68: 1718 ‐ 1725. | en_US |
dc.identifier.citedreference | Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008; 79: 1331 ‐ 1338. | en_US |
dc.identifier.citedreference | Jokinen P, Scheinin N, Aalto S, et al. [(11)C]PIB‐, [(18)F]FDG‐PET and MRI imaging in patients with Parkinson's disease with and without dementia. Parkinsonism Relat Disord 2010; 16: 666 ‐ 670. | en_US |
dc.identifier.citedreference | Petrou M, Bohnen NI, Müller ML, Koeppe RA, Albin RL, Frey KA. Abeta‐amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology 2012; 79: 1161 ‐ 1167. | en_US |
dc.identifier.citedreference | Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25. | en_US |
dc.identifier.citedreference | Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50: 140 ‐ 148. | en_US |
dc.identifier.citedreference | Larsen JP, Dupont E, Tandberg E. Clinical diagnosis of Parkinson's disease: proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand 1994; 89: 242 ‐ 251. | en_US |
dc.identifier.citedreference | American Psychiatric Association. Diagnostic criteria from DSM‐IV‐TR. 2000, Washington, DC: American Psychiatric Association, xii, 370 p. | en_US |
dc.identifier.citedreference | Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003; 327: 557 ‐ 560. | en_US |
dc.identifier.citedreference | Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985; 42: 1097 ‐ 1105. | en_US |
dc.identifier.citedreference | Jack CR, Jr., Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging‐Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 2012; 71: 765 ‐ 775. | en_US |
dc.identifier.citedreference | Wolk DA, Grachev ID, Buckley C, et al. Association between in vivo fluorine 18‐labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 2011; 68: 1398 ‐ 1403. | en_US |
dc.identifier.citedreference | Sojkova J, Driscoll I, Iacono D, et al. In vivo fibrillar beta‐amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol 2011; 68: 232 ‐ 240. | en_US |
dc.identifier.citedreference | Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446 ‐ 452. | en_US |
dc.identifier.citedreference | Mielke MM, Wiste HJ, Weigand SD, et al. Indicators of amyloid burden in a population‐based study of cognitively normal elderly. Neurology 2012; 79: 1570 ‐ 1577. | en_US |
dc.identifier.citedreference | Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA. APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010; 67: 122 ‐ 131. | en_US |
dc.identifier.citedreference | Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31: 1275 ‐ 1283. | en_US |
dc.identifier.citedreference | Fleisher AS, et al. Florbetapir PET analysis of amyloid‐beta deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross‐sectional study. Lancet Neurol 2012; 11: 1057 ‐ 1065. | en_US |
dc.identifier.citedreference | Jack CR, Jr., Wiste HJ, Weigand SD, et al. Age‐specific population frequencies of cerebral beta‐amyloidosis and neurodegeneration among people with normal cognitive function aged 50‐89 years: a cross‐sectional study. Lancet Neurol 2014; 13: 997 ‐ 1005. | en_US |
dc.identifier.citedreference | Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837 ‐ 844. | en_US |
dc.identifier.citedreference | Cirrito JR, Disabato BM, Restivo JL, et al. Serotonin signaling is associated with lower amyloid‐beta levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A 2011; 108: 14968 ‐ 14973. | en_US |
dc.identifier.citedreference | Kotagal V, Bohnen NI, Müller ML, Koeppe RA, Frey KA, Albin RL. Cerebral amyloid deposition and serotoninergic innervation in Parkinson disease. Arch Neurol 2012; 69: 1628 ‐ 1631. | en_US |
dc.identifier.citedreference | Scheinin NM, Wikman K, Jula A, et al. Cortical 11 C‐PIB uptake is associated with age, APOE genotype, and gender in “healthy aging.” J Alzheimers Dis 2014; 41: 193 ‐ 202. | en_US |
dc.identifier.citedreference | Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008; 115: 409 ‐ 415. | en_US |
dc.identifier.citedreference | Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh‐Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8‐year prospective study. Arch Neurol 2003; 60: 387 ‐ 392. | en_US |
dc.identifier.citedreference | Boot B. The incidence and prevalence of dementia with Lewy bodies is underestimated. Psychol Med 2013; 43: 2687 ‐ 2688. | en_US |
dc.identifier.citedreference | Vann Jones SA, O'Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med 2014; 44: 673 ‐ 683. | en_US |
dc.identifier.citedreference | McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863 ‐ 1872. | en_US |
dc.identifier.citedreference | Jellinger KA. Significance of brain lesions in Parkinson disease dementia and Lewy body dementia. Front Neurol Neurosci 2009; 24: 114 ‐ 125. | en_US |
dc.identifier.citedreference | Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007; 68: 812 ‐ 819. | en_US |
dc.identifier.citedreference | Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 2011; 122: 187 ‐ 204. | en_US |
dc.identifier.citedreference | Tsuboi Y, Uchikado H, Dickson DW. Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology. Parkinsonism Relat Disord 2007; 13 (Suppl 3 ): S221 ‐ S224. | en_US |
dc.identifier.citedreference | Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B. Ann Neurol 2004; 55: 306 ‐ 319. | en_US |
dc.identifier.citedreference | Compta Y, Parkkinen L, O'Sullivan SS, et al. Lewy‐ and Alzheimer‐type pathologies in Parkinson's disease dementia: which is more important? Brain 2011; 134: 1493 ‐ 1505. | en_US |
dc.identifier.citedreference | Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. Striatal beta‐amyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol 2008; 67: 155 ‐ 161. | en_US |
dc.identifier.citedreference | Burke JF, Albin RL, Koeppe RA, Giordani B, Kilbourn MR, Gilman S, Frey KA. Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. Brain 2011; 134 (Pt 6 ): 1647 ‐ 1657. | en_US |
dc.identifier.citedreference | Kantarci K, Lowe VJ, Boeve BF, et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging 2012; 33: 2091 ‐ 2105. | en_US |
dc.identifier.citedreference | Maetzler W, Liepelt I, Reimold M, et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer‐like characteristics. Neurobiol Dis 2009; 34: 107 ‐ 112. | en_US |
dc.identifier.citedreference | Foster ER, Campbell MC, Burack MA, et al. Amyloid imaging of Lewy body‐associated disorders. Mov Disord 2010; 25: 2516 ‐ 2523. | en_US |
dc.identifier.citedreference | Shimada H, Shinotoh H, Hirano S, et al. beta‐Amyloid in Lewy body disease is related to Alzheimer's disease‐like atrophy. Mov Disord 2013; 28: 169 ‐ 175. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.